OCT 30, 2018 1:24 PM PDT

Re-sensitizing Drug-resistant Human Tumor Cells

WRITTEN BY: Nouran Amin

Understanding how cancer cells avoid death despite their DNA being damaged will create new strategies to enhance cancer cell killing through chemotherapy treatment. Even though the most widely used drugs are DNA-damaging agents (DDAs), their therapeutic success has been often halted by drug resistance. Addressing the challenges of drug resistance is crucial in the field of clinical cancer treatments.

Watch the short video below to learn more about drug-resistant cancer:

Now, a recent study published in the Nature Structural and Molecular Biology discusses a new way of re-sensitizing drug-resistant human tumor cells to the potency of DDAs and paving the way to new strategies to overcome chemotherapeutic drug resistance.

The researchers found that protein, called Schlafen 11, inhibits the production of two other proteins ATM and ATR that are found in tumor cells. "We found that if you expose cells that have Schlafen 11 to DNA damaging agents, the Schlafen 11 protein gets activated and suppresses the synthesis of ATM and ATR -- that's essentially what kills the tumor cells," explains Professor Michael David, a professor in the Biological Sciences Section of Molecular Biology and UC San Diego Moores Cancer Center. "In cells that do not express Schlafen 11, you do not get this downregulation of ATM/ATR and that essentially allows the tumor cells to survive."

Credit: Manqing Li, Michael David Lab, UC San Diego

Image: “Pancreatic cancer cells deficient in the expression of the human gene known as Schlafen 11 and resistant to chemotherapy (left panels) were re-sensitized to chemotherapeutic treatment (middle and right panels) by inhibiting the expression of the transfer RNA known as tRNA-Leu-TAA through specially designed antisense oligonucleotides.”- ScienceDaily

Digging deeper into the mechanism of Schlafen 11 works on a molecular level, the researchers discovered that most of the genes involved in DNA damage repair pathways will display a similar skewing of their transfer RNA seen in HIV, specifically towards tRNA-Leu-TAA—prompting a new tecnhique to re-sensitize Schlafen 11-deficient tumor cells to drugs via the targeting of tRNA-Leu-TAA.

Such intervention may influence the entire DNA damage repair pathway -- including ATM and ATR – to not just inhibit the function of one specific component at a time. "These results suggest two ways to enhance the killing of cancer cells by DNA-damaging drugs by adding 1) ATR inhibitors or 2) tRNA inhibitors," said study coauthor Jean Wang, professor emeritus in UC San Diego's School of Medicine. "The paper is also of significance to the basic research on DNA damage response because it shows for the first time that regulation of tRNAs determines when a damaged cell will survive or die."

Despite being relevant to DNA damage and cancer, the research holds applications in immunology and virology, particularly in HIV treatments, because of the fundamental mechanisms behind Schlafen 11.

Source: Nature Structural & Molecular Biology, Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
SEP 27, 2021
Microbiology
Rift Valley Fever's Infectious Secret is Revealed
SEP 27, 2021
Rift Valley Fever's Infectious Secret is Revealed
Rift Valley fever virus is carried by mosquitoes, and when it's passed to livestock including cattle, goats, and sheep, ...
SEP 28, 2021
Drug Discovery & Development
The FDA approves drug to treat a bad cholesterol in children
SEP 28, 2021
The FDA approves drug to treat a bad cholesterol in children
Familial hypercholesterolemia (FH) is a genetic disorder that afflicts approximately 1 in 250 people. Interestingly, whi ...
OCT 26, 2021
Immunology
Two Different Arms, Twice the Cancer-Killing Potential?
OCT 26, 2021
Two Different Arms, Twice the Cancer-Killing Potential?
Our immune system has developed an arsenal of sophisticated molecular weapons to defend us against the continuous barrag ...
OCT 27, 2021
Drug Discovery & Development
A novel drug delivery device to treat macular degeneration.
OCT 27, 2021
A novel drug delivery device to treat macular degeneration.
Last Friday, October 22nd, the United States Food and Drug Administration (FDA) approved a first of its kind d ...
NOV 12, 2021
Cannabis Sciences
Battle of the Cannabinoids: Which Cannabis Compound Could Most Effectively Treat IBD?
NOV 12, 2021
Battle of the Cannabinoids: Which Cannabis Compound Could Most Effectively Treat IBD?
With 3 million people from the U.S. reporting clinical cases in 2015 – accompanied by an increased projected incid ...
NOV 17, 2021
Drug Discovery & Development
FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system
NOV 17, 2021
FDA greenlights clinical trials for novel COVID-19 vaccine and delivery system
Last week the United States Food and Drug Administration (FDA) authorized the biotechnology company Inovio to ...
Loading Comments...